Article
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.
Nature - 1 May 2024
Wasko Urszula N, Jiang Jingjing, Dalton Tanner C, Curiel-Garcia Alvaro, Edwards A Cole, Wang Yingyun, Lee Bianca, Orlen Margo, Tian Sha, Stalnecker Clint A, Drizyte-Miller Kristina, Menard Marie, Dilly Julien, Sastra Stephen A, Palermo Carmine F, Hasselluhn Marie C, Decker-Farrell Amanda R, Chang Stephanie, Jiang Lingyan, Wei Xing, Yang Yu C, Helland Ciara, Courtney Haley, Gindin Yevgeniy, Muonio Karl, Zhao Ruiping, Kemp Samantha B, Clendenin Cynthia, Sor Rina, Vostrejs William P, Hibshman Priya S, Amparo Amber M, Hennessey Connor, Rees Matthew G, Ronan Melissa M, Roth Jennifer A, Brodbeck Jens, Tomassoni Lorenzo, Bakir Basil, Socci Nicholas D, Herring Laura E, Barker Natalie K, Wang Junning, Cleary James M, Wolpin Brian M, Chabot John A, Kluger Michael D, Manji Gulam A, Tsai Kenneth Y, Sekulic Miroslav, Lagana Stephen M, Califano Andrea, Quintana Elsa, Wang Zhengping, Smith Jacqueline A M, Holderfield Matthew, Wildes David, Lowe Scott W, Badgley Michael A, Aguirre Andrew J, Vonderheide Robert H, Stanger Ben Z, Baslan Timour, Der Channing J, Singh Mallika, Olive Kenneth P
Abstract excerpt
Broad-spectrum RAS inhibition has the potential to benefit roughly a quarter of human patients with cancer whose tumours are driven by RAS mutations1,2. RMC-7977 is a highly selective inhibitor of the active GTP-bound forms of KRAS, HRAS and NRAS, with affinity for both mutant and wild-type variants3. More than 90% of cases of human pancreatic ductal adenocarcinoma (PDAC) are driven by activating mutations in...
Read the complete abstract on PubMed